IL13RA2 and glioblastoma: Subjects with GBM that highly expressed IL-13Rα2 mRNA (Log2 ratio ≥ 2) had a median survival of 335 days (n = 175) compared to 384 days for subjects with IL-13Rα2 negative tumors (n = 122) (Fig. 2a).